Benchmark Capital Advisors increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 78.1% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,298 shares of the company’s stock after purchasing an additional 3,200 shares during the quarter. Benchmark Capital Advisors’ holdings in Johnson & Johnson were worth $886,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Financial Gravity Wealth Inc. bought a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $105,000. FNY Investment Advisers LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $117,000. Princeton Capital Management LLC bought a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $141,000. Smart Portfolios LLC bought a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $150,000. Finally, Live Your Vision LLC grew its stake in shares of Johnson & Johnson by 58.3% during the 2nd quarter. Live Your Vision LLC now owns 1,363 shares of the company’s stock worth $172,000 after acquiring an additional 502 shares in the last quarter. 66.67% of the stock is owned by institutional investors and hedge funds.
In other news, CAO Ronald A. Kapusta sold 7,899 shares of the stock in a transaction that occurred on Friday, September 7th. The stock was sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the sale, the chief accounting officer now owns 25,725 shares of the company’s stock, valued at approximately $3,528,955.50. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Michael E. Sneed sold 29,000 shares of the firm’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $134.80, for a total value of $3,909,200.00. Following the sale, the chief operating officer now directly owns 59,124 shares of the company’s stock, valued at approximately $7,969,915.20. The disclosure for this sale can be found here. Corporate insiders own 0.22% of the company’s stock.
Several brokerages have recently weighed in on JNJ. Wells Fargo & Co reaffirmed an “outperform” rating and set a $160.00 price target on shares of Johnson & Johnson in a research note on Friday, September 14th. Jefferies Financial Group set a $145.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Sunday, July 15th. HC Wainwright reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday, October 17th. Credit Suisse Group set a $149.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Sunday, October 14th. Finally, ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the stock. Johnson & Johnson currently has a consensus rating of “Hold” and an average price target of $141.54.
NYSE JNJ opened at $139.05 on Monday. The company has a market capitalization of $373.06 billion, a PE ratio of 19.05, a P/E/G ratio of 2.17 and a beta of 0.70. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.65 and a quick ratio of 1.33. Johnson & Johnson has a 12 month low of $118.62 and a 12 month high of $148.32.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, beating the consensus estimate of $2.03 by $0.02. The company had revenue of $20.35 billion during the quarter, compared to the consensus estimate of $20.05 billion. Johnson & Johnson had a return on equity of 34.97% and a net margin of 1.89%. The firm’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.90 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 8.16 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Stockholders of record on Tuesday, November 27th will be issued a $0.90 dividend. This represents a $3.60 annualized dividend and a dividend yield of 2.59%. The ex-dividend date of this dividend is Monday, November 26th. Johnson & Johnson’s payout ratio is presently 49.32%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.